|
시장보고서
상품코드
1761154
세계의 항비만제 시장 규모와 예측(2021-2031년) : 세계 및 지역 점유율, 동향, 성장 기회 분석 보고서 : 유형, 약제 클래스, 용도, 투여 경로, 유통 채널, 지역별Anti-obesity Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Application, Route of Administration, and Distribution Channel, and Geography |
||||||
당사의 최신 조사 보고서인 "항비만제 세계 시장 예측(-2031년) - 세계 분석 : 유형, 약물 유형, 용도, 투여 경로, 유통 채널, 지역별 분석"에 따르면, 시장 규모는 2024년 158억 5,000만 달러에서 2031년 1,772억 7,000만 달러에 달할 것으로 예측됩니다. 2025-2031년 35.3%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 비만 유병률 증가, 체중 관리 솔루션에 대한 인식과 수요 증가는 항비만제 시장 규모 확대에 기여하고 있습니다. 그러나 부작용과 안전성에 대한 우려가 항비만제 시장의 성장을 저해하고 있습니다. 또한, 정밀의료와 개인 맞춤형 항비만제 요법은 향후 몇 년 동안 새로운 항비만제 시장 동향을 가져올 것으로 예측됩니다.
수익 측면에서 북미는 2024년 시장을 장악했습니다. 예측 기간 동안에도 세계 시장을 지배할 것으로 예측됩니다. 미국은 세계 최대의 항비만제 시장입니다. The International Journal of Tissue Repair and Regeneration에 따르면, 미국 인구의 1%에서 활동성 또는 치유된 정맥성 궤양이 발생하며, 미국 질병예방센터(CDC)의 간행물인 The International Journal of Tissue Repair and Regeneration에 따르면, 미국 인구의 1%에서 활동성 또는 치유된 정맥성 궤양이 발생한다고 합니다. 미국 질병예방통제센터(CDC)의 간행물인 National Diabetes Statistics Report 2020에 따르면, 미국에서는 모든 연령대에서 3,420만 명이 당뇨병을 앓고 있으며, 매년 100만 명의 당뇨병 환자가 족부궤양을 앓고 있고, 600-700만 명의 당뇨병 환자가 평생 궤양을 앓고 있습니다. 이처럼 당뇨병과 만성 상처의 유병률 증가는 상처 드레싱에 대한 수요 증가로 이어져 예측 기간 동안 항비만제 시장의 성장에 기여하고 있습니다. 미국 기업들은 유기적 및 무기적 전략을 채택하여 입지를 확대하는 데 주력하고 있으며, 2021년 10월 Medline Industries는 캔자스 주에 새로운 물류 센터를 건설하기 위해 7,750만 달러를 투자할 것이라고 발표했습니다.
항비만제 시장 분석
신흥국 확대는 향후 시장 기회를 가져올 것입니다.
2023년 7월에 발표된 Lancet의 연구에 따르면, 2050년까지 인도에서 약 4억 5,000만 명의 성인이 과체중 또는 비만이 될 것으로 예상되며, 2021년에는 과체중 또는 비만으로 분류되는 전 세계 성인의 절반 이상이 다음과 같은 국가에 집중되어 있습니다. 1억 8,000만 명, 중국 4억 2,000만 명, 브라질 8,800만 명, 러시아 7,100만 명, 멕시코 5,800만 명, 인도네시아 5,200만 명, 이집트 4,100만 명입니다.
세계비만연맹에 따르면, 베트남, 인도네시아, 방글라데시에서는 비만 유병률이 증가하고 있으며, 그 비율은 지난 수십년동안 6-9%에 달하고 있습니다. 도시화, 좌식 생활, 식습관의 변화로 인해 신흥국에서 비만 유병률이 증가함에 따라 항비만제에 대한 수요가 증가하고 있습니다. 인구의 상당수가 미진단 또는 미치료 상태로 남아 있어 제약사가 새로운 치료법을 도입하고 도달 범위를 확대할 수 있는 미개척 시장으로 남아 있습니다. 일라이 릴리는 2026년까지 인도, 브라질, 멕시코에서 체중감량 및 당뇨병 치료제 틸제파타이드(당뇨병 치료제 Mounjaro, 항비만제 Zepbound로 판매)를 출시할 준비를 하고 있습니다.
브라질은 의료 인프라 및 비만 관리 프로그램을 강화하고 새로운 항비만제 도입과 상환을 지원하는 환경을 조성하고 있으며, 2024년 4월 상파울루 주 홀트란디아에 오젬픽의 활성 성분인 리라글루티드를 포함한 당뇨병 및 비만 치료제를 전문적으로 생산하는 연구소를 설립했습니다. EMS가 운영하는 이 공장에서는 오젠픽의 주성분인 세마글루타이드도 생산됩니다. 이 세마글루티드는 2026년 3월까지 유효한 특허를 보유하고 있으며, 이미 ANVISA(Agencia Nacional de Vigilancia Sanitaria)의 심사를 받은 상태이며, 6,000만 헤알(약 1,093만 달러)을 투자한 이 시설은 브라질 최초의 시설입니다. 연방정부의 보건경제산업단지 구상을 지원하는 것입니다.
세계경제포럼에 따르면, 항비만제에 대한 초기 접근은 민간 시장과 자부담으로 제한될 수 있습니다. 그러나 향후 보험이 적용되고 중산층 국가에서도 제네릭 의약품이 사용되기 시작하면 이러한 의약품에 대한 접근성이 개선될 수 있습니다. 이처럼 비만율 증가, 정부 지원책, 제품 혁신은 신흥국 시장에 미래 성장 기회를 가져올 것으로 예측됩니다.
항비만제 시장 세분화 분석
항비만제 시장 분석에 기여한 주요 부문은 유형, 약물 유형, 투여 경로, 용도, 유통 채널입니다.
유형별로 항비만제 시장은 처방약과 일반의약품으로 구분되며, 2024년에는 처방약 부문이 상대적으로 큰 점유율을 차지할 것으로 예측됩니다.
약효군별로 항비만제 시장은 GLP-1 작용제, 리파제 억제제, MC4R 작용제, 기타로 분류되며, 2024년에는 GLP-1 작용제 부문이 가장 큰 시장 점유율을 차지했으며, GLP-1 작용제 부문은 세마글루티드, 리라글루티드, 티르제파타이드 등으로 세분화됩니다. 틸세파타이드 등으로 세분화됩니다.
용도별로 항비만제 시장은 식욕억제, 지방흡수 및 소화효소 억제, 대사촉진, 복합제로 분류되며, 2024년 시장에서는 식욕억제 부문이 가장 큰 비중을 차지할 것으로 예측됩니다.
투여 경로에 따라 항비만제 시장은 경구용과 비경구용으로 나뉘며, 2024년에는 경구용 부문이 시장을 장악했습니다.
유통 채널별로 항비만제 시장은 병원 내 약국, 온라인 채널, 소매 약국으로 분류되며, 2024년에는 병원 내 약국 부문이 시장을 장악할 것으로 예측됩니다.
항비만제 시장 : 경쟁 구도와 주요 발전
Novo Nordisk AS, Eli Lilly & Company, GSK Plc, Rhythm Pharmaceuticals Inc, Curax Pharmaceuticals LLC, Vivas LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, F. Hoffman-La Roche Ltd. 등이 항비만제 시장에서 사업을 전개하고 있는 주요 기업들입니다.
항비만제 시장 보고서를 작성할 때 참고한 1차 및 2차 정보는 세계보건기구, 세계 비만 아틀라스, 미국 식품의약국, 랜싯 저널, 세계 비만 연맹, 세계경제포럼, 질병통제예방센터(CDC), 국제당뇨병연맹(IDF), 경제협력개발기구(OECD) 등입니다. 입니다.
목차
제1장 서론
제2장 주요 요약
- 애널리스트 시장 전망
제3장 조사 방법
- 2차 조사
- 1차 조사
- 가설 책정
- 거시경제 요인 분석
- 기초 수치 작성
- 데이터 삼각측량
- 국가 레벨 데이터
- 가정과 한계
제4장 항비만제 시장 구도
- PEST 분석
제5장 항비만제 시장 : 주요 시장 역학
- 항비만제 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 향후 동향
- 성장 촉진요인과 억제요인의 영향
제6장 항비만제 시장 : 세계 시장 분석
- 항비만제 시장 매출, 2021년-2031년
- 항비만제 시장 예측 분석
제7장 항비만제 시장 분석 : 유형별
- 처방약
- OTC 의약품
제8장 항비만제 시장 분석 : 약제 클래스별
-
GLP-1 아고니스트, 리파아제 억제제, MC4R 아고니스트
- GLP-1 아고니스트
- 리파아제 억제제
- MC4R 아고니스트
- 기타
제9장 항비만제 시장 분석 : 용도별
- 식욕 억제
- 지방 흡수 및 소화 효소 저해
- 대사 촉진
- 병용
제10장 항비만제 시장 분석 : 투여 경로별
- 경구
- 비경구
제11장 항비만제 시장 분석 : 유통 채널별
- 원내 약국
- 온라인 채널
- 소매 약국
제12장 항비만제 시장 분석 : 지역별
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 독일
- 영국
- 프랑스
- 스페인
- 이탈리아
- 기타 유럽
- 아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
- 중남미
- 브라질
- 아르헨티나
- 기타 중남미
제13장 업계 상황
- 신제품 개발/승인
- 기타 사업 전략
제14장 기업 개요
- Novo Nordisk AS
- Eli Lilly and Co
- GSK Plc
- Rhythm Pharmaceuticals Inc
- Currax Pharmaceuticals LLC.
- VIVUS LLC
- AdvaCare Pharma USA LLC
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd
제15장 기업 개요 부록
LSH 25.07.08According to our new research study on "Anti-obesity Drugs Market Forecast to 2031 -Global Analysis - by Type, Drug Class, Route of Administration, Application, Distribution Channel, and Geography," the market is anticipated to grow from US$ 15.85 billion in 2024 and is projected to reach US$ 177.27 billion by 2031; it is expected to register a CAGR of 35.3% during 2025-2031. Mounting prevalence of obesity and increased awareness and demand for weight management solutions are contributing to the growing anti-obesity drugs market size. However, the side effects and safety concerns hamper the anti-obesity drugs market growth. Further, precision medicine and personalized anti-obesity drug regimens is expected to bring in new anti-obesity drugs market trends in the coming years.
In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for anti-obesity drugs in the world. Chronic wounds associated with diabetes include foot, venous, and pressure ulcers. According to The International Journal of Tissue Repair and Regeneration, active or healed venous ulcers occur in 1% of the US population. As per the National Diabetes Statistics Report 2020, a publication of the Centers for Disease Control and Prevention (CDC), 34.2 million people of all ages in the US have diabetes, and ~1 million diabetics develop a foot ulcer each year, while 6-7 million diabetes patients develop ulcers in their lifetime. Thus, the rising incidence of diabetes and chronic wounds leads to an increase in demand for wound dressing and contributes to the anti-obesity drugs market growth during the forecast period. Companies in the US are focused on expanding their presence by adopting organic and inorganic strategies. In October 2021, Medline Industries announced an investment of US$ 77.5 million to build a new distribution center in Kansas.
Anti-obesity Drugs Market Analysis
Expansion in Emerging Economies to Provide Market Opportunities in Future
According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.
According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6-9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.
Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolandia, Sao Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026 and is already under review by Agencia Nacional de Vigilancia Sanitaria (ANVISA). With an investment of R$60 million (~US$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.
According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. Thus, the rising obesity rates, supportive government initiatives, and product innovations are expected to create future growth opportunities for the market in emerging countries.
Anti-obesity Drugs Market Report Segmentation Analysis
Key segments that contributed to the derivation of the anti-obesity drugs market analysis are type, drug class, route of administration, application, and distribution channel.
Based on type, the anti-obesity drugs market is bifurcated into prescription and OTC. The prescription segment held relatively larger share of the market in 2024.
By drug class, the anti-obesity drugs market is segmented into GLP-1 agonists, lipase inhibitors, MC4R agonists, and others. The GLP-1 Agonist segment held the largest share of the market in 2024. GLP-1 agonists segment further subsegmented into Semaglutide, Liraglutide, Tirzepatide.
Based on application, the anti-obesity drugs market is categorized into appetite suppression, inhibition of fat absorption/digestive enzymes, metabolic enhancement, and combination. The appetite suppression segment held a largest share of the market in 2024.
In terms of route of administration, the anti-obesity drugs market is bifurcated into oral and parenteral. The oral segment dominated the market in 2024.
Per distribution channel, the anti-obesity drugs market is categorized into hospital pharmacies, online channel, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.
Anti-obesity Drugs Market: Competitive Landscape and Key Developments
Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are among the key companies operating in the anti-obesity drugs market.
The World Health Organization, World Obesity Atlas, The U.S. Food and Drug Administration, The Lancet Journal, World Obesity Federation, World Economic Forum, Centers for Disease Control and Prevention (CDC), the International Diabetes Federation (IDF), the Organization for Economic Co-operation and Development (OECD) are primary and secondary sources referred to while preparing the anti-obesity drugs market report.
Table Of Contents
1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Analyst Market Outlook
3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
- 3.3 Assumptions and Limitations
4. Anti-Obesity Drugs Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
5. Anti-Obesity Drugs Market - Key Market Dynamics
- 5.1 Anti-Obesity Drugs Market - Key Market Dynamics
- 5.2 Market Drivers
- 5.2.1 Mounting Prevalence of Obesity
- 5.2.2 Increased Awareness and Demand for Weight Management Solutions
- 5.3 Market Restraints
- 5.3.1 Side Effects and Safety Concerns
- 5.4 Market Opportunities
- 5.4.1 Expansion in Emerging Economies
- 5.5 Future Trends
- 5.5.1 Precision Medicine and Personalized Anti-Obesity Drug Regimens
- 5.6 Impact of Drivers and Restraints:
6. Anti-Obesity Drugs Market - Global Market Analysis
- 6.1 Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
- 6.2 Anti-Obesity Drugs Market Forecast Analysis
7. Anti-Obesity Drugs Market Analysis - by Type
- 7.1 Prescription Drugs
- 7.1.1 Overview
- 7.1.2 Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 7.2 OTC Drugs
- 7.2.1 Overview
- 7.2.2 OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8. Anti-Obesity Drugs Market Analysis - by Drug Class
- 8.1 GLP-1 Agonist
- 8.1.1 Overview
- 8.1.2 GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 8.2 Lipase Inhibitors
- 8.2.1 Overview
- 8.2.2 Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 8.3 MC4R agonist
- 8.3.1 Overview
- 8.3.2 MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9. Anti-Obesity Drugs Market Analysis - by Application
- 9.1 Appetite Suppression
- 9.1.1 Overview
- 9.1.2 Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 9.2 Inhibition of Fat Absorption or Digestive Enzymes
- 9.2.1 Overview
- 9.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 9.3 Metabolic Enhancement
- 9.3.1 Overview
- 9.3.2 Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 9.4 Combination
- 9.4.1 Overview
- 9.4.2 Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10. Anti-Obesity Drugs Market Analysis - by Route Of Administration
- 10.1 Oral
- 10.1.1 Overview
- 10.1.2 Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 10.2 Parenteral
- 10.2.1 Overview
- 10.2.2 Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
11. Anti-Obesity Drugs Market Analysis - by Distribution Channel
- 11.1 Hospital Pharmacies
- 11.1.1 Overview
- 11.1.2 Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2 Online Channel
- 11.2.1 Overview
- 11.2.2 Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 11.3 Retail Pharmacies
- 11.3.1 Overview
- 11.3.2 Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
12. Anti-Obesity Drugs Market - Geographical Analysis
- 12.1 Overview
- 12.2 North America
- 12.2.1 North America Anti-Obesity Drugs Market Overview
- 12.2.2 North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.2.3 North America: Anti-Obesity Drugs Market Breakdown, by Type
- 12.2.3.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.2.4 North America: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.2.4.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.2.4.1.1 North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.2.4.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.2.5 North America: Anti-Obesity Drugs Market Breakdown, by Application
- 12.2.5.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.2.6 North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.2.6.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.2.7 North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.2.7.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.2.8 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.2.8.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.2.8.2 United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.2.8.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Type
- 12.2.8.2.2 United States: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.2.8.2.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.2.8.2.3 United States: Anti-Obesity Drugs Market Breakdown, by Application
- 12.2.8.2.4 United States: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.2.8.2.5 United States: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.2.8.3 Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.2.8.3.1 Canada: Anti-Obesity Drugs Market Breakdown, by Type
- 12.2.8.3.2 Canada: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.2.8.3.2.1 Canada: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.2.8.3.3 Canada: Anti-Obesity Drugs Market Breakdown, by Application
- 12.2.8.3.4 Canada: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.2.8.3.5 Canada: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.2.8.4 Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.2.8.4.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Type
- 12.2.8.4.2 Mexico: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.2.8.4.2.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.2.8.4.3 Mexico: Anti-Obesity Drugs Market Breakdown, by Application
- 12.2.8.4.4 Mexico: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.2.8.4.5 Mexico: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.3 Europe
- 12.3.1 Europe Anti-Obesity Drugs Market Overview
- 12.3.2 Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.3.3 Europe: Anti-Obesity Drugs Market Breakdown, by Type
- 12.3.3.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.3.4 Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.3.4.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.3.4.1.1 Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.4.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.3.5 Europe: Anti-Obesity Drugs Market Breakdown, by Application
- 12.3.5.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.3.6 Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.3.6.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.3.7 Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.3.7.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.3.8 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.3.8.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.3.8.2 Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.3.8.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Type
- 12.3.8.2.2 Germany: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.3.8.2.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.8.2.3 Germany: Anti-Obesity Drugs Market Breakdown, by Application
- 12.3.8.2.4 Germany: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.3.8.2.5 Germany: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.3.8.3 United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.3.8.3.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Type
- 12.3.8.3.2 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.3.8.3.2.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.8.3.3 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Application
- 12.3.8.3.4 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.3.8.3.5 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.3.8.4 France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.3.8.4.1 France: Anti-Obesity Drugs Market Breakdown, by Type
- 12.3.8.4.2 France: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.3.8.4.2.1 France: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.8.4.3 France: Anti-Obesity Drugs Market Breakdown, by Application
- 12.3.8.4.4 France: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.3.8.4.5 France: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.3.8.5 Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.3.8.5.1 Spain: Anti-Obesity Drugs Market Breakdown, by Type
- 12.3.8.5.2 Spain: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.3.8.5.2.1 Spain: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.8.5.3 Spain: Anti-Obesity Drugs Market Breakdown, by Application
- 12.3.8.5.4 Spain: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.3.8.5.5 Spain: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.3.8.6 Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.3.8.6.1 Italy: Anti-Obesity Drugs Market Breakdown, by Type
- 12.3.8.6.2 Italy: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.3.8.6.2.1 Italy: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.8.6.3 Italy: Anti-Obesity Drugs Market Breakdown, by Application
- 12.3.8.6.4 Italy: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.3.8.6.5 Italy: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.3.8.7 Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.3.8.7.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Type
- 12.3.8.7.2 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.3.8.7.2.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.3.8.7.3 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Application
- 12.3.8.7.4 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.3.8.7.5 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4 Asia Pacific
- 12.4.1 Asia Pacific Anti-Obesity Drugs Market Overview
- 12.4.2 Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.4.3 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type
- 12.4.3.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.4.4 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.4.4.1.1 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.4.5 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application
- 12.4.5.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.4.6 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.6.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.4.7 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.7.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.4.8 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.4.8.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.4.8.2 China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.4.8.2.1 China: Anti-Obesity Drugs Market Breakdown, by Type
- 12.4.8.2.2 China: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.4.8.2.2.1 China: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.8.2.3 China: Anti-Obesity Drugs Market Breakdown, by Application
- 12.4.8.2.4 China: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.8.2.5 China: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.8.3 Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.4.8.3.1 Japan: Anti-Obesity Drugs Market Breakdown, by Type
- 12.4.8.3.2 Japan: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.4.8.3.2.1 Japan: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.8.3.3 Japan: Anti-Obesity Drugs Market Breakdown, by Application
- 12.4.8.3.4 Japan: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.8.3.5 Japan: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.8.4 India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.4.8.4.1 India: Anti-Obesity Drugs Market Breakdown, by Type
- 12.4.8.4.2 India: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.4.8.4.2.1 India: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.8.4.3 India: Anti-Obesity Drugs Market Breakdown, by Application
- 12.4.8.4.4 India: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.8.4.5 India: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.8.5 Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.4.8.5.1 Australia: Anti-Obesity Drugs Market Breakdown, by Type
- 12.4.8.5.2 Australia: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.4.8.5.2.1 Australia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.8.5.3 Australia: Anti-Obesity Drugs Market Breakdown, by Application
- 12.4.8.5.4 Australia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.8.5.5 Australia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.8.6 South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.4.8.6.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Type
- 12.4.8.6.2 South Korea: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.4.8.6.2.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.8.6.3 South Korea: Anti-Obesity Drugs Market Breakdown, by Application
- 12.4.8.6.4 South Korea: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.8.6.5 South Korea: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.8.7 Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.4.8.7.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Type
- 12.4.8.7.2 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.4.8.7.2.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.4.8.7.3 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Application
- 12.4.8.7.4 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.8.7.5 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.5 Middle East and Africa
- 12.5.1 Middle East and Africa Anti-Obesity Drugs Market Overview
- 12.5.2 Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.5.3 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
- 12.5.3.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.5.4 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.5.4.1.1 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.5.5 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
- 12.5.5.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.5.6 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.5.6.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.5.7 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.5.7.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.5.8 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.5.8.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.5.8.2 Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.5.8.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Type
- 12.5.8.2.2 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.5.8.2.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.5.8.2.3 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Application
- 12.5.8.2.4 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.5.8.2.5 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.5.8.3 South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.5.8.3.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Type
- 12.5.8.3.2 South Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.5.8.3.2.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.5.8.3.3 South Africa: Anti-Obesity Drugs Market Breakdown, by Application
- 12.5.8.3.4 South Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.5.8.3.5 South Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.5.8.4 United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.5.8.4.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Type
- 12.5.8.4.2 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.5.8.4.2.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.5.8.4.3 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Application
- 12.5.8.4.4 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.5.8.4.5 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.5.8.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.5.8.5.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
- 12.5.8.5.2 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.5.8.5.2.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.5.8.5.3 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
- 12.5.8.5.4 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.5.8.5.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.6 South and Central America
- 12.6.1 South and Central America Anti-Obesity Drugs Market Overview
- 12.6.2 South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
- 12.6.3 South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
- 12.6.3.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
- 12.6.4 South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.6.4.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.6.4.1.1 South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.6.4.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
- 12.6.5 South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
- 12.6.5.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
- 12.6.6 South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.6.6.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
- 12.6.7 South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.6.7.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.6.8 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.6.8.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
- 12.6.8.2 Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.6.8.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Type
- 12.6.8.2.2 Brazil: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.6.8.2.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.6.8.2.3 Brazil: Anti-Obesity Drugs Market Breakdown, by Application
- 12.6.8.2.4 Brazil: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.6.8.2.5 Brazil: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.6.8.3 Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.6.8.3.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Type
- 12.6.8.3.2 Argentina: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.6.8.3.2.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.6.8.3.3 Argentina: Anti-Obesity Drugs Market Breakdown, by Application
- 12.6.8.3.4 Argentina: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.6.8.3.5 Argentina: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.6.8.4 Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 12.6.8.4.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
- 12.6.8.4.2 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
- 12.6.8.4.2.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
- 12.6.8.4.3 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
- 12.6.8.4.4 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.6.8.4.5 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
13. Industry Landscape
- 13.1 Overview
- 13.2 New Product Development/Approval
- 13.3 Other Business Strategies
14. Company Profiles
- 14.1 Novo Nordisk AS
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.2 Eli Lilly and Co
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 GSK Plc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.4 Rhythm Pharmaceuticals Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 Currax Pharmaceuticals LLC.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 VIVUS LLC
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 AdvaCare Pharma USA LLC
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.9 Sun Pharmaceutical Industries Ltd
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
- 14.10 F. Hoffmann-La Roche Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
15. Appendix
- 15.1 About The Insight Partners
- 15.2 Glossary of Terms
